GCVTX
Price
$23.30
Change
-$0.04 (-0.17%)
Updated
Jun 5 closing price
Net Assets
519.04M
RMEBX
Price
$57.64
Change
-$0.04 (-0.07%)
Updated
Jun 5 closing price
Net Assets
105.31B
Interact to see
Advertisement

GCVTX vs RMEBX

Header iconGCVTX vs RMEBX Comparison
Open Charts GCVTX vs RMEBXBanner chart's image
Goldman Sachs Large Cp Val Insghts I
Price$23.30
Change-$0.04 (-0.17%)
VolumeN/A
Net Assets519.04M
American Funds American Mutual R2E
Price$57.64
Change-$0.04 (-0.07%)
VolumeN/A
Net Assets105.31B
GCVTX vs RMEBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GCVTX vs. RMEBX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GCVTX is a Buy and RMEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMEBX has more cash in the bank: 105B vs. GCVTX (519M). RMEBX pays higher dividends than GCVTX: RMEBX (1.16) vs GCVTX (1.09). GCVTX was incepted earlier than RMEBX: GCVTX (18 years) vs RMEBX (11 years). RMEBX (1.07) is less costly to investors than GCVTX (0.77). GCVTX is a more actively managed with annual turnover of: 206.00 vs. RMEBX (31.00). GCVTX has a lower initial minimum investment than RMEBX: GCVTX (0) vs RMEBX (250). RMEBX annual gain was more profitable for investors over the last year : 8.30 vs. GCVTX (-2.81). RMEBX return over 5 years is better than : 49.85 vs. GCVTX (23.66).
GCVTXRMEBXGCVTX / RMEBX
Total Expense Ratio0.671.0763%
Annual Report Gross Expense Ratio0.771.0772%
Fund Existence18 years11 years-
Gain YTD1.5545.34929%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets519M105B0%
Annual Yield % from dividends1.091.1694%
Returns for 1 year-2.818.30-34%
Returns for 3 years8.9017.9650%
Returns for 5 years23.6649.8547%
Returns for 10 years54.4368.2180%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VERV5.720.43
+8.22%
Verve Therapeutics
VRNT18.780.97
+5.45%
Verint Systems
CHRS0.80N/A
+0.48%
Coherus Oncology Inc
CHSCN25.15-0.05
-0.20%
CHS
PRI265.13-2.99
-1.12%
PRIMERICA